Fundraising Fox
SR One Capital Management
Venture capitalActively deployingRedwood City · Seed–Series B · 31 people tracked
Also known as SR ONE CAPITAL MANAGEMENT, LP
Find your way into SR One Capital Management
Sign up to see every warm intro you have to SR One Capital Management
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SR One Capital Management team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
SR One is a biotechnology venture capital firm that backs companies translating novel science into medicines. It uses a 'back-and-build' approach, focusing on companies with strong fundamentals, a clearly defined development pathway, and novel approaches to treating disease. With an investing team based in West Coast biotech hubs in the USA and in London, UK, the firm leverages its transatlantic footprint to act as a strategic partner, offering geographic reach and regional expertise to source opportunities and provide real-time business support to portfolio companies.
Source: firm website, verified Oct 17, 2026.
Team · 31 people
from the firm's website & curated & public directories
Simeon J. George is CEO and co-founder of SR One Capital Management, a trans-Atlantic biotechnology venture capital firm that spun out of GSK in 2020 and maintains offices in the Bay Area and London. The firm invests in biotechnology companies with the aim of developing new medicines for areas of unmet medical need.
A Managing Director at Spectrum Equity, shown in conversation with portfolio company leaders.
Jake Nunn is a Partner at SR One focusing on later-stage private and public biotech investments, with over 25 years in the life sciences industry as an investor, board director, research analyst, and investment banker. He was previously an investing partner at New Enterprise Associates (NEA) from 2006 to 2019, where he founded the firm's public healthcare investing practice, and earlier held roles at MPM Capital, Franklin Templeton Investments, and Alex. Brown & Sons. He holds an MBA from Stanford Graduate School of Business and a BA in Economics from Dartmouth College, and is a CFA charterholder.
Rajeev Dadoo is COO and Managing Partner at SR One, which he joined in 2004, and is an alum of the Kauffman Fellows Program. He invests in therapeutics and healthcare-technology companies, drawing on operational and strategic experience from prior roles at GSK's Competitive Excellence group, Genentech, Bio-Rad Laboratories, and Genome Therapeutics, and he co-founded Unimicro Technologies. He holds a BA in Chemistry and Mathematics from Knox College, a PhD in Chemistry from Stanford University, and an MBA from the Wharton School.
Amit Shah is a Principal in SR One's London office, focusing on venture capital investments in biotech. Before joining SR One in early 2018, he held roles at GlaxoSmithKline spanning late-phase clinical development, global medical affairs, and early pipeline commercial strategy, and he is a board-certified-equivalent plastic surgeon specializing in microsurgical cancer reconstruction. He holds a B.A. in Medical Sciences, an M.A. in Neuroscience, and an M.D. from the University of Cambridge, and since 2020 has served on the venture capital panel for the BioInnovation Institute.
Laetitia Schwab is a Principal at SR One in the London office, joining in 2022. She previously worked in clinical development at Orchard Therapeutics, contributing to the delivery of the gene therapy Libmeldy for Marketing Authorisation, and has experience across early and late-phase clinical programs with expertise in gene therapy, neuroscience, and rare diseases. She holds a B.Sc in Medical Sciences from the University of Edinburgh, an MPhil in Translational Medicine and a Ph.D in Clinical Neuroscience from the University of Cambridge, and an MBA from INSEAD.
Amit Mehta is a Venture Partner at SR One, which he joined in 2024, and serves as COO and CBO at Dren Bio, an SR One portfolio company. He previously spent 18 years at Genentech, most recently as Vice President and Head of Business Development, where he worked on drug development, product strategy, and strategic partnerships. He holds a B.E. in Chemical Engineering from Bangalore University and a Ph.D. in Chemical Engineering from Pennsylvania State University.
Matt Patterson is a Venture Partner at SR One Capital Management with over 30 years in the research, development, and commercialization of therapeutics. He co-founded Audentes Therapeutics in 2012 and served as CEO until its 2020 acquisition by Astellas Pharma, and previously worked at Genzyme, BioMarin Pharmaceutical, Amicus Therapeutics, and Iris Medicine, as well as serving as an Entrepreneur-In-Residence at OrbiMed. He holds a Bachelor's degree in Biochemistry from Bowdoin College.
Executive Assistant and Office Manager at Sandbox Industries (joined 2023), providing executive support to Emir Sandhu. Previously a special education teacher.
Jake Bauer is a Venture Partner at SR One who works with emerging clinical biotechnology companies. He previously served as Chief Business Officer of MyoKardia, which was acquired by Bristol Myers Squibb in 2020, and held earlier roles at Ablexis, Third Rock Ventures, Royalty Pharma, Endo Pharmaceuticals, and Putnam Associates. He holds a BS in Biology and BA in Economics from Duke University and an MBA from Harvard Business School.
Alicia Hasson joined SR One in 2024, working out of the San Francisco Bay Area office where she provides executive administrative support to Rajeev Dadoo, Jill Carroll, and Jake Nunn. She has 15 years of administrative experience in the biotech industry across large and small pharmaceutical companies. She studied Business Administration at City College of San Francisco.
Ann Ng is the Finance Director at SR One, based in the firm's London office, where she manages accounting, financial statements, and fund reporting while supporting the CFO on operations. She previously spent ten years at CITIC Capital Partners Limited in private equity fund management and operations. She holds a BA in Accounting & Finance from Curtin University of Technology and is a CPA (Australia).
Briana Wilson joined SR One in 2023 and provides administrative support to team members as well as assisting with event planning. She previously worked at Huntsman Gay Global Capital, where she handled administrative support, reception, and vendor relations. She holds a Bachelor of Science in Kinesiology from San Jose State University.
Catalina Kazi is Legal and Compliance Counsel at SR One, which she joined in 2024. She previously worked for over five years as in-house counsel handling regulatory compliance at retail and institutional investment managers, and served as an attorney in the Securities Division of the Secretary of the Commonwealth of Massachusetts. She holds a B.A. in International Relations from Florida International University and a J.D. from Boston University School of Law, and is licensed to practice law in New York and Registered In-House Counsel in California.</bio_summary> <parameter name="investments">[]
Chris Chai is an Operating Partner at SR One who advises portfolio companies on financing strategy, Wall Street engagement, and execution. He has more than 20 years of experience in biotech executive management and investment banking, having served as CFO at Principia Biopharma and MAP Pharmaceuticals and in treasury and investor relations at CV Therapeutics, and earlier held investment banking roles at JP Morgan. He holds a BS in Operations Research and Industrial Engineering from Cornell University.
Frances Benson joined SR One in 2020 as Chief of Staff, overseeing business functions such as operations, events, marketing, and PR. She previously worked at Sofinnova Investments, where she handled administrative support, reception, and vendor relations. She studied Interior Architecture and Design at the Academy of Arts University in San Francisco.
Iqbal Mufti is an Operating Partner at SR One's London office, working on company creation, later-stage investments, and portfolio companies' industry engagement and partnering strategy. He previously worked at Hoffmann-La Roche, where he co-led the rare blood disorders portfolio strategy team and served as global Lifecycle Leader for Hemlibra (emicizumab). His background covers pharmaceutical product and portfolio strategy, late-stage development, global commercialization, business development, and M&A. He holds a BSc in Biotechnology from University College London and an MBA from Duke University's Fuqua School of Business.
James Macadam is Chief Financial Officer at SR One, based in the firm's London office, where he oversees financial matters and helps manage a range of the firm's operations. He joined SR One in 2019 after holding corporate finance and commercial roles at GlaxoSmithKline. He holds an MA in Geography from Oxford University, an MPhil in Polar Studies from Cambridge University, and an MBA from HEC Paris.</bio_summary> <parameter name="investments">[]
Jill Carroll is an Operating Partner at SR One, which she first joined in 2011, and manages several of the firm's investments. She holds a BS in Chemistry from Duke University and an MS in Biochemistry from Johns Hopkins University. Before SR One, she worked in strategy consulting and biotech corporate development, including at Dynavax Technologies.
Serves as a board member in connection with SR One's portfolio company Rezo Therapeutics.
Lyla Youssef is an Associate at SR One, based in the San Francisco Bay Area, where she joined in 2024 with a background in biotechnology and therapeutics equities. She previously worked as an Associate Analyst covering therapeutics at Hudson Bay Capital, in biotech equity research as a Vice President at TD Cowen, and in equity research at Oppenheimer & Co., along with roles at Columbia University's Translational Therapeutics Accelerator and Columbia Tech Ventures. She holds a Ph.D. in Microbiology & Immunology from Columbia University and a B.A. in Biological Sciences and Economics from Cornell University.
Mahesh Kudari is a Senior Associate at SR One's London office, which he joined in 2024. He previously served as VP Business Operations at Xap Therapeutics and Head of Clinical Development at Orchard Therapeutics, where he led cross-functional gene therapy development programs, and earlier held early clinical development and medical affairs roles at GSK. He holds a medical degree from University College London and an M.A. in Medical Sciences from the University of Cambridge, and has a background in diagnostic and interventional radiology.
Mary Mirt joined SR One in 2025, where she provides administrative and office management support to team members. She previously held office management roles at Peakspan Capital and Pacific Lake Partners, handling vendor management and reception. She holds a Bachelor of Arts in Communication & Media Studies from CSU East Bay.
Philip Habib leads SR One's Capital Partnering effort and is based in London, with over 15 years of experience across venture capital, private equity, and real estate. He began his career in the Private Equity & Venture Capital group at Cambridge Associates advising institutional investors, and later worked at General Electric in Business Development (M&A) and Sponsor Leveraged Finance, covering sectors including healthcare. He holds an MBA from London Business School and an MA in Economics from the University of Edinburgh.
Sasha Keough serves as General Counsel and Chief Compliance Officer at SR One, which she joined in 2022. She previously spent over 12 years as an in-house attorney at New Enterprise Associates, working on compliance, venture capital financings, and fund operations. She holds a B.A. in History from the University of Virginia and a J.D. from the University of Baltimore School of Law.
Tanya McGlashan joined SR One in October 2020, where she oversees risk, financial, and operational functions. Previously she worked at an investment bank managing data analytics projects and business support, and earlier held roles in accounts, compliance, and operations at a private equity and HNWI family office. She holds a BA in English and Spanish from N. Novgorod Linguistic University, a Diploma in Professional Accounting (AAT), and ACCA certificates in management accounts, performance management, taxation, and corporate/business law.
Viraj Pillai is the Finance Director at SR One, based in the London office, where he oversees the fund's accounting, financial statements, and reporting, and works with external stakeholders and suppliers. He has over ten years of post-qualification experience, including five years with fund administrators and earlier work as an auditor at PwC (Sri Lanka/Botswana) and Deloitte UK. He holds a chartered accountancy qualification from the Institute of Chartered Accountants of Sri Lanka and is an associate member of the Institute of Certified Management Accountants.
Founder mafia
6 people who came through SR One Capital Management went on to found or lead other companies.
What they invest in
from 56 of 77 portfolio companiesBiotech ×51Healthtech ×35Medical Devices ×14Deep Tech ×9AI & Machine Learning ×6Digital Health ×5Construction Tech ×1Enterprise Software ×1
HQs:United States×36United Kingdom×4Canada×1Switzerland×1Denmark×1
Who they back
founder profiles across 24 portfolio companiesFounding team size:solo founder×82 founders×93 founders×54+ founders×2
Where their founders studiedfrom 13 founders with education data
Massachusetts Institute of Technology ×3
What their founders studiedfrom 12 founders with field-of-study data
Life Sciences ×5Chemistry ×3Engineering ×2
Where their founders worked beforefrom 18 founders with career history
InterMune ×2Rigimmune ×2University of California, San Francisco ×2
Investments · 77 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 52024 · 32023 · 42022 · 52021 · 42020 · 52019 · 12018 · 12017 · 12016 · 52015 · 141 dated
Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
BiotechHealthtechGeneva
Roger Mills(Executive Officer, Director)inMikhail Kalinichev(Executive Officer)inJean-Philippe Rocher(Executive Officer)inRobert Lutjens(Executive Officer)inTimothy Dyer(Executive Officer, Director)Vincent Lawton(Director)
Board seatJake Nunn· per SEC Form D · $3.7M raise · filed Apr 2023
Co-investorsNew Enterprise Associates (NEA)Sofinnova PartnersACORN BIOVENTURES
Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.
BiotechHealthtechWest Hartford, US
Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)
Board seatKatarina Pance· per SEC Form D
Co-investorsLongitude CapitalConnecticut InnovationsLifeSci Venture PartnersOUP (Osage University Partners)abrdn plcInvus
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Board seatJake Nunn· per SEC Form D
Co-investorsDelos CapitalLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersPivotal Life SciencesQuan Capital+3 more
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalGeneral AtlanticHBM Healthcare InvestmentsHBM PartnersNextech InvestOrbiMed+4 more
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersPivotal Life Sciences+9 more
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge, GB
Gregory Winter(Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalDementia Discovery FundLongwood FundRidgeback Capital+4 more
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.
BiotechMedical DevicesSolana Beach, US
Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)
BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)
Co-investorsAvoro Capital AdvisorsQuan CapitalRA CapitalWellington ManagementWestRiver Group
A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
BiotechArlington, US
Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTodd Bazemore(Executive Officer)inMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in
Co-investorsLongitude CapitalWellington ManagementYsios CapitalAtlas VentureLux CapitalRA Capital+1 more
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Co-investorsAndera PartnersHBM Healthcare InvestmentsHBM PartnersSamsara BioCapitalYsios CapitalAdams Street Partners+3 more
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.
BiotechHealthtechSouth San Francisco, US
Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)in
BoardMichael Dybbs(Director)Jill Carroll(Director)inTiba Aynechi(Director)in
Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalAmgen VenturesLogosNorwest Venture Partners+1 more
Oruka is a biopharmaceutical company developing monoclonal antibody therapies aimed at treating plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory conditions with fewer annual doses.
BiotechHealthtech
Lawrence Klein(Chief Executive Officer and Director)in
Co-investorsViking Global
Progyny provides employer-sponsored women's health and family-building benefits, covering preconception, fertility, pregnancy and postpartum, and menopause/midlife care through concierge support, digital tools, and a managed network of specialists.
Digital HealthFemTechHealthtechHR Tech
Gina Bartasi(Founder)inPeter Anevski(Chief Executive Officer and Director)
Co-investorsAurumKleiner PerkinsM VenturesSavano Capital PartnersUnion Grove Venture Partners
ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.
BiotechHealthtechMedical DevicesSan Diego, US
Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)inRobert A. MacLeod(Chief Scientific Officer)inChristopher Claeboe(Senior Vice President of Operations)in
Co-investorsBain Capital Life SciencesOrbiMedLilly Asia VenturesT. Rowe PriceAscenta CapitalTCG Crossover+3 more
Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team.
BiotechHealthtechSouth San Francisco, US
Kathleen Collins(Director)inLawrence Kong(Executive Officer)inRon Park(President & CEO)inFrancine Gregoire(Chief Scientific Officer)inPriya Parameswaran(Chief Business Officer)in
BoardJayson Punwani(Director)in
Board seatLaetitia SchwabMatthew R. Patterson· per SEC Form D
Co-investorsBEVCPivotal Life SciencesAbingworth
ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.
BiotechHealthtechMedical DevicesSan Diego, US
Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)
BoardJonathan Leff(Director)
Board seatRajeev Dadoo· per SEC Form D
Co-investorsNextech InvestOrbiMedRA CapitalSofinnova Ventures
CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.
BiotechDeep TechHealthtechZug, CH
Emmanuelle Charpentier(Founder)Samarth Kulkarni(Chief Executive Officer and Chairman of the Board)inJames R. Kasinger(General Counsel and Secretary)inStephen Kennedy(Head of Technical Operations)inMegan Wherry Menner(Head of Human Resources)inNaimish Patel(Chief Medical Officer)in
Board seatSimeon J. George· per SEC Form D
Co-investorsAvoro Capital AdvisorsCLI VenturesKhosla VenturesNew Enterprise Associates (NEA)Versant VenturesWellington Management+2 more
HealthtechMenlo Park, US
Thomas G. Wiggans(Executive Officer, Director)inEugene A. Bauer(Executive Officer, Director)Andrew Guggenhime(Executive Officer)Luis Pena(Executive Officer)Christopher Griffith(Executive Officer)
BoardFred Craves(Director)in
Board seatJake Nunn· per SEC Form D · $1M raise · filed Dec 2018
Co-investorsAisling CapitalBay City CapitalCanaan PartnersForesite CapitalNew Enterprise Associates (NEA)Fidelity Investments+1 more
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Founder)
BoardIvan Trifunovich(Director)John Wesley(Founder)
Board seatRajeev Dadoo· per SEC Form D
Co-investors8VCAisling CapitalHBM Healthcare InvestmentsHBM PartnersJacket River Capital PartnersMission Bay Capital+5 more
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inAlan Crane(Director)inMarian Nakada(Director)inBrian Gallagher(Director)in
Board seatRajeev Dadoo· per SEC Form D · $20.2M raise · filed May 2020
Co-investorsage1Brace PharmaSanofi VenturesAtlas VenturePolaris Partners
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)inGary D. Glick(Founder)Gary D. Glick, Ph.D.(Founder, President & CEO)
BoardCarl Gordon(Director)inValerie Odegard(Director)
Board seatJill Carroll· per SEC Form D
Co-investorsActivant CapitalAscenta CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess Fund+9 more
Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.
BiotechDigital HealthMedical DevicesWaltham, US
Jim Broderick(Co-Founder)inJohn Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)Li Peng(Chief Scientific Officer)
Board seatRajeev Dadoo· per SEC Form D
Co-investorsMatrix Capital ManagementPfizer VenturesPfizer Venture InvestmentsBioHealth Innovation, Inc.Takeda VenturesVertex Ventures HC
Regulus Therapeutics was a San Diego-based clinical-stage biopharmaceutical company developing oligonucleotide drugs that inhibit disease-causing microRNAs.
BiotechHealthtechSan Diego, US
Neil Gibson(Executive Officer)Kleanthis Xanthopoulos(Executive Officer, Director)
BoardB. Lynne Parshall(Director)Mark G. Foletta(Director)John Maraganore(Director)Douglas E. Williams(Director)
Board seatJake Nunn· per SEC Form D · $34.6M raise · filed Dec 2021
Co-investorsForesite CapitalNew Enterprise Associates (NEA)
Endologix develops medical devices and therapies for treating vascular disease, focusing on interventions such as EVAR (endovascular aneurysm repair) procedures.
HardwareHealthtechMedical DevicesSanta Rosa, US
Michael V. Chobotov(Executive Officer)inSHARI L. O'QUINN(Executive Officer)inMichael R. Kramer(Executive Officer)KIMBERLEY ELTING(Executive Officer)CHRISTOPHER CHAVEZ(Executive Officer, Director)VIVEK K. JAYARAMAN(Executive Officer)in
Board seatJake Nunn· per SEC Form D · $10M raise · filed Aug 2015
Co-investors415 CapitalKaiser Permanente VenturesNew Enterprise Associates (NEA)Deerfield Management Company
46 Capital is an investment firm focused on early-stage companies across multiple sectors, led by experienced professionals with backgrounds in venture capital, private equity, healthcare, energy, and finance.
Fintech
Tim Clark(Managing Director)
Co-investorsHurricane VenturesAndreessen HorowitzAscenta CapitalAvaana CapitalBoxGroupClaypond Capital+7 more
Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.
BiotechPalo Alto, US
James Li(Executive Officer, Director)Maria Fardis(Executive Officer, Director)in
BoardAnna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)Jill Carroll(Director)in
Co-investorsFrazier Life SciencesLongitude CapitalOrbiMed
Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsARCH Venture PartnersIP GroupLundbeckfonden VenturesWestlake Village BioPartners
Ancora Biotech is a privately held biotherapeutics developer overseeing the manufacturing and clinical development of three multi-specific antibodies held in separate spin-offs.
BiotechHealthtech
Co-investorsLightspeed Venture PartnersSutter Hill Ventures
Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.
BiotechHealthtechCopenhagen, DK
Jens Juul Holst(Founder)Mette Rosenkilde(Founder)in
Co-investorsBroadview VenturesNovo HoldingsVersant Ventures
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in
BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSamsara BioCapitalSixty Degree CapitalSolasta Ventures+4 more
Co-investorsAvego BioScience CapitalBioGenerator VenturesPerot JainRiverVest Venture PartnersRoche Venture Fund
Biotech
Co-investorsKurma PartnersSofinnova PartnersJohnson & Johnson Innovation – JJDCM VenturesEQT Life Sciences
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
BiotechSan Diego, US
Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in
BoardCarl Gordon(Director)
Co-investorsDelos CapitalForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMed+6 more
Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease.
BiotechDeep TechMedical DevicesSan Diego, US
Kyle Chan, PhD(Executive Officer)Lawrence Zaslow(Executive Officer, Director)inFrank Mercurio, PhD(Executive Officer)Leah Fung(Chief Executive Officer & Board Member (former Chief Scientific Officer))inRaymond W. Urbanski(Acting Chief Medical Officer)inPhilippe Drouet(Chief Executive Officer)in
Co-investorsLumira VenturesRevelation Partners
CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches.
AI & Machine LearningBiotechHealthtechLondon
Lakshyaditya Singh Aithani(Executive Officer, Director)David Baker(Founder)Laksh Aithani(Founder)
BoardRishi Gupta(Director)inNihal Sinha(Director)inMuzammil Mansuri(Director)in
Co-investorsF-Prime CapitalNew Enterprise Associates (NEA)NVIDIAOrbiMedAxial VCKhosla Ventures+1 more
Codify Therapeutics is a discovery-stage biotech developing cancer therapeutics that target abnormal alternative RNA splicing, such as in splicing-factor-mutant leukemias.
Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.
BiotechDeep TechDigital HealthMedical DevicesCardiff, GB
John Atack(Head of Biology & Founder)inSimon Ward(Chief Scientific Officer & Founder)in
Co-investorsAccess BiotechnologyCanaan PartnersSanofi VenturesSV Health InvestorsBritish Business BankCanaan Healthcare+1 more
Econic Biosciences is a biotech company developing cancer therapies that target extrachromosomal DNA (ecDNA), a driver of oncogene amplification and tumor evolution.
BiotechDeep TechHealthtechLondon, GB
Ralph Lindemann(Chief Scientific Officer)Pete Johnson(Head of Medicinal Chemistry)Steven Whittaker(Head of Biology)inAlastair Hamilton(Head of Business Operations & Strategy)in
BoardRodger Novak(Executive Chairman)in
Elektrofi is a biotech company developing an ultra-high concentration microparticle formulation platform that enables subcutaneous delivery of biologic medicines such as monoclonal antibodies.
BiotechDeep TechHealthtechMedical DevicesBoston, US
Chase Coffman(Chief Executive Officer & Co-founder)inSam Huang(Director)Jason Norris(Co-founder)Charles L. Cooney(Director)Andrew Goldberg(Director)Constatine Chinoporos(Director)
Co-investorsBiotechnology Value FundNovo HoldingsCatalio Capital Management, LPCharlotte Angel FundGeneral CatalystRA Capital+1 more
.png)
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsHBM Healthcare InvestmentsHBM PartnersLG Technology VenturesNovartis Venture FundOrbiMedPontifax Venture Capital+4 more
HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.
AI & Machine LearningBiotechHealthtech
BoardBruce Booth(Chairman)in
Co-investorsAtlas VentureB Capital GroupB4 CapitalMRL Ventures FundPivotal Life SciencesSofinnova Partners+2 more
.jpeg){kind=logo}
BiotechEast Providence, US
Manny Avila(Executive Officer, Director)inDirk Kuyper(Executive Officer, Director)inRobert Rabiner(Executive Officer)
BoardDaniel Omstead(Director)Fouad Azzam(Director)inRajeev Dadoo(Director)
Co-investorsPappas CapitalEQT Life Sciences
Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis.
BiotechMedical Devices
Mark Pepys(Co-founder; Emeritus Professor of Medicine at UCL)Gregory Winter(Co-founder; Nobel Laureate)Daniel Christ(Co-founder; Professor, Faculty of Medicine, UNSW)
Co-investorsCambridge Innovation CapitalFrazier Life SciencesQiming Venture PartnersF-Prime Capital
Kartos Therapeutics develops targeted small-molecule therapeutics aimed at treating patients with solid tumors and hematological cancers.
BiotechHealthtech
Co-investorsOrbiMed
Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.
BiotechHealthtech
Co-investorsPfizer Venture InvestmentsRoche Venture FundRosetta Capital Ltd.Sofinnova PartnersIP Group
Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.
AI & Machine LearningBiotechDeep TechHealthtech
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesDementia Discovery FundGV (Google Ventures)Lightstone Ventures+4 more
Nomic is an AI platform for architecture, engineering, and construction (AEC) teams that orchestrates agents across drawings, specs, submittals, RFIs, and building codes to automate coordination and review work.
AI & Machine LearningConstruction TechEnterprise Software
Brandon Duderstadt(Founder)inAndriy Mulyar(Founder)Ben Schmidt(Founder)
Co-investorsBetaworksCoatue ManagementContrary2048 VenturesDynamk CapitalLux Capital
Nomic offers an end-to-end protein profiling service built on its nELISA technology, quantifying up to 1000 informative proteins with absolute quantification for research studies.
BiotechDeep TechHealthtechMedical DevicesMontreal, CA
Milad Dagher(Founder)inJeff Munzar(Founder)inElisha Krauss(Operations Manager)Ani Muradyan(Recruiter)
Co-investorsAmplitude Venture CapitalAvant BioFirst Star VenturesFront Row VenturesRaptor GroupY Combinator+9 more
Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.
BiotechCambridge, US
Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)inAnthony Coyle(Executive Officer, Director)inChristopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)
Co-investorsAccess BiotechnologyJDRF T1D FundMission BiocapitalRA CapitalPolaris PartnersVersant Ventures
Poplar Therapeutics is a company whose website provides informational content; based on its name it operates in therapeutics/biotech, though the available page (a privacy policy) does not describe its specific products or focus.
Biotech
Co-investorsRA CapitalVida Ventures
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)in
BoardPETER THOMPSON(Director)inSRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Co-investorsAccess BiotechnologyMission BiocapitalSofinnova VenturesMission Bay CapitalNew Leaf Venture PartnersOrbiMed+1 more
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalAsahi Kasei Corporate Venture CapitalDementia Discovery FundF-Prime CapitalJeito CapitalLongwood Fund+4 more
Rezo maps disease networks to find insights into disease biology for drug discovery.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Nevan Krogan(Co-Founder)inSourav Bandyopadhyay(Co-Founder)inNorbert Bischofberger(Co-Founder)Natalia Jura(Co-Founder)George Scangos(Co-Founder)Kevan Shokat(Co-Founder)
Co-investorsAndreessen HorowitzNorwest Venture PartnersHAWKTAILValkyrie Ventures Management, LlcARCH Venture PartnersSV Angel
Co-investorsLifeforce CapitalPfizer Venture InvestmentsRoche Venture FundDigitalis VenturesLightstone VenturesMorgenthaler
Simcha is a biotechnology company developing new cancer medicines based on immune biology research.
BiotechHealthtechNew Haven, US
Aaron Ring(Executive Officer, Director)inBeatrice McQueen(Chief Operating Officer)inSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)
Co-investorsConnecticut InnovationsPfizer Venture InvestmentsAxial VCBiotechnology Value FundRock Springs CapitalSamsara BioCapital
Telios Pharma is a clinical-stage biopharmaceutical company developing first-in-class topical and oral BTK-inhibitor drugs targeting mast-cell-mediated inflammation, including TL-925 for dry eye disease.
Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases.
BiotechHealthtechCambridge, US
Hui Tian(Executive Officer, Director)inMadgalene Moran(Executive Officer, Director)Magdalene Moran(Chief Executive Officer)
BoardKarin Kleinhans(Director)Bruce Bean(Director)James Jeffrey Goater, Jr.(Director)
Co-investorsMRL Ventures FundThe Column Group
Co-investorsVivo CapitalRemiges Ventures, Inc.
Co-investorsForesite CapitalLAVLilly Asia VenturesNextech InvestSv Tech Ventures, Inc.HBM Partners
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.
BiotechHealthtech
Co-investorsOrbiMedQuan CapitalRA CapitalSanofi VenturesJanus Henderson InvestorsNovo Holdings+3 more
Xap Therapeutics uses genome editing and synthetic biology to engineer a programmable cell-based delivery platform that carries therapeutic payloads such as cytokines, antibodies, and nucleic acids, releasing them upon target recognition.
BiotechDeep TechCambridge, GB
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Bird Rock BioEntasis Therapeutics HoldingsAlios BiopharmaARS PharmaCorxel Pharmaceuticals LimitedCrystalys Therapeutics, Inc.Decibel TherapeuticsiPierianKartos TherapeuticsMorphic TherapeuticNimbusRenalysRenalys PharmaRiver RenalRiver VisionTrue North TherapeuticsVibrant Biomedicines
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 19
12 IPOs · 7 acquisitions · showing 18Addex TherapeuticsNASDAQ: ADXNVeradermicsNYSE: MANEZenas BiopharmaNASDAQ: ZBIOAlumisNASDAQ: ALMSAvalyn Pharma IncNASDAQ: AVLNBicycleNASDAQ: BCYCDesigntxNASDAQ: DSGNKALA BIONASDAQ: KALAMineralys TherapeuticsNASDAQ: MLYSNkarta, Inc.NASDAQ: NKTXOruka Therapeutics IncNASDAQ: ORKAProgynyNASDAQ: PGNYBird Rock Bioacq. by Skye BioscienceRegulus Therapeutics Inc.acq. by NovartisTrivascularacq. by EndologixDecibel Therapeuticsacq. by RegeneronPandion Therapeuticsacq. by MerckRenalysacq. by Chugai Pharmaceutical Co., Ltd.
Portfolio news
latest coverage across their companiesCRISPR · massbio.org · Sep 6, 2026
Veradermics · biospace.com · Sep 4, 2026
Fore Biotherapeutics · technical.ly · Aug 6, 2026
Draig Therapeutics · finsmes.com · Jul 14, 2026
Arcellx · startupintros.com · Jul 13, 2026
Antag Therapeutics · globenewswire.com · May 21, 2026
Windward Bio · finsmes.com · May 5, 2026
Fund performance · per public LP disclosures · 2
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| SR One Capital Fund II-A, LPLPs: California Public Employees' Retirement System | 2023 | — | — | 0.89x | 0.04x |
| SR One Capital Opportunities Fund I, LPLPs: California Public Employees' Retirement System | 2023 | — | — | 0.63x | 0.00x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Avalyn Pharma Inc | 6.6% | $18.00 | Apr 2026 | $49.6M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has SR One Capital Management made?
- SR One Capital Management has 77 tracked investments, 19 of which have exited, including 7 dated in the last 24 months.
- What stage does SR One Capital Management invest at?
- SR One Capital Management invests at the Seed, Series A, Series B stages.
- What sectors does SR One Capital Management focus on?
- SR One Capital Management focuses on Biotech, Healthtech, Medical Devices.
- Where is SR One Capital Management located?
- SR One Capital Management is headquartered in Redwood City, US.
- Who does SR One Capital Management co-invest with?
- SR One Capital Management most often shares deals with OrbiMed, RA Capital, New Enterprise Associates (NEA), among 104 tracked co-investors.
- What size deals does SR One Capital Management back?
- Across 16 deals with disclosed amounts, SR One Capital Management has joined rounds of $13M – $220M (median $57.5M).
Co-investors · 42
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
HBM Partners is a Swiss healthcare-focused asset manager that invests in private and public companies across biopharma, medtech, diagnostics and healthcare, supporting portfolio companies through all stages of development.
Atlas Venture is a biotechnology-focused venture firm that creates and builds breakthrough life science companies, backing entrepreneurs to translate scientific research into new medicines.
Pivotal Life Sciences is a global healthcare investment firm backing companies developing high-impact therapeutics for major unmet medical needs, operating across venture capital, venture building, and public equity strategies.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
Roche Venture Fund is the corporate venture arm of Roche, investing in life science companies across pharmaceuticals, diagnostics and digital health to foster innovation and generate financial returns.
Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.
▶30 more co-investors
ARCH Venture PartnersEQT Life SciencesVersant VenturesAndreessen HorowitzGeneral CatalystGV (Google Ventures)Kleiner PerkinsB Capital GroupCanaan PartnersPolaris PartnersJohnson & Johnson Innovation – JJDCThird Rock VenturesAbingworthNovartis Venture FundAisling CapitalLightstone VenturesRiverVest Venture PartnersOUP (Osage University Partners)5AM VenturesThe Column GroupMorgenthalerKurma PartnersRemiges Ventures, Inc.VenrockHighbury HoldingsMPM BioImpactStanford UniversityAdvent Life SciencesDolby Family Ventures3B Future Health Fund
Firms observed investing alongside SR One Capital Management, from public investor directories. Shared companies are the overlap with SR One Capital Management's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is an independent manager of venture capital funds and the listed investment company Quest for Growth, backing innovative companies that use technology as a competitive advantage.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.